 |
|
Potential new approach to treat cognitive impairments in schizophrenia
September 25, 2007A new study reports important evidence for a potential new treatment approach for those diagnosed with schizophrenia. Schizophrenia is considered one of the most devastating of the major psychiatric disorders, which has three distinct facets, often referred to as "positive" (hallucinations, delusions), "negative" (blunted emotions, reduced capacity for pleasure), and "cognitive" (impairments in attention, memory, and problem-solving) symptoms. The cognitive impairments associated with schizophrenia are the aspect of this disorder most strongly associated with the inability to function in the workplace.
The medications currently approved to treat schizophrenia block a subclass of dopamine receptors (dopamine D2 receptors). They have limited efficacy in treating the negative and cognitive symptoms of this disorder and they are frequently associated with significant side effects. "Hence, there is an acute need to develop alternative treatments for schizophrenia that have fewer side effects and are more effective in treating cognitive and negative symptoms of the disorder," according to the authors of this study, scheduled for publication in Biological Psychiatry on October 1st.
"Multidisciplinary work has led to the emergence of the glutamate system as a promising therapeutic target for [the] treatment of schizophrenia," says Bita Moghaddam, Ph.D., the corresponding author on the study. Abnormal function of brain circuits that utilize glutamate as a chemical messenger, particularly in brain regions including the prefrontal cortex and hippocampus, has been implicated in the cognitive deficits associated with schizophrenia. The glutamate-related circuit dysfunction associated with schizophrenia may be modeled, to a meaningful extent, by blocking the NMDA subtype of glutamate receptor. The authors now report that by administering 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide or CDPPB, a drug that stimulates another type of glutamate receptor, the metabotropic glutamate 5 receptor (mGluR5), they can normalize abnormalities in prefrontal cortical function produced by blocking the NMDA glutamate receptor. In other words, CDPPB appears to "treat" an abnormality in brain function that may resemble aspects of schizophrenia.
Dr. Moghaddam comments, "This work is significant because it shows that in an awake behaving mammal (as opposed to in tissue cultures or similar preparation), activation of these receptors has a normalizing effect on the spontaneous activity of prefrontal cortex neurons." John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, adds, "These exciting new data provide important new evidence supporting the testing of mGluR5 stimulating medications for the treatment of schizophrenia, particularly cognitive deficits associated with impairments in the function of the prefrontal cortex. It would be very interesting to know whether this class of medication reduces the transient impairments in cognitive function associated with the administration of NMDA receptor blockers to humans." Although the authors acknowledge that much more research is needed to evaluate the clinical impact of this treatment approach, this study indicates a "promising therapeutic potential" that could ultimately result in making improved treatments available to patients struggling with this illness.
Elsevier
Dr. Moghaddam comments, "This work is significant because it shows that in an awake behaving mammal (as opposed to in tissue cultures or similar preparation), activation of these receptors has a normalizing effect on the spontaneous activity of prefrontal cortex neurons." John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, adds, "These exciting new data provide important new evidence supporting the testing of mGluR5 stimulating medications for the treatment of schizophrenia, particularly cognitive deficits associated with impairments in the function of the prefrontal cortex. It would be very interesting to know whether this class of medication reduces the transient impairments in cognitive function associated with the administration of NMDA receptor blockers to humans." Although the authors acknowledge that much more research is needed to evaluate the clinical impact of this treatment approach, this study indicates a "promising therapeutic potential" that could ultimately result in making improved treatments available to patients struggling with this illness.
Elsevier
Schizophrenia Current Events and Schizophrenia News RSSPrognosis after attempted suicide impaired by psychiatric disorder
People who have attempted suicide at some point in their lives are more likely to actually succeed in committing suicide at a later date.
Routine Testing After Aneurysm Coiling Carries Low Risk
A very low risk of complication is associated with a routine test that determines whether a brain aneurysm treated with endovascular coiling has started to recur, a study led by the University of Cincinnati Neuroscience Institute has shown.
Protein can nurture or devastate brain cells, depending on its 'friends,' researchers find
Researchers at UT Southwestern Medical Center have uncovered new insights into the "Dr. Jekyll and Mr. Hyde" nature of a protein that stimulates stem-cell maturation in the brain but, paradoxically, can also lead to nerve-cell damage.
Pivotal Emory study focuses on teens at risk for psychosis
Emory University in Atlanta is playing a key role in the largest, most comprehensive study ever funded by the National Institute of Mental Health (NIMH) of adolescents and young adults at risk for developing a psychotic disorder.
Interaction between gene variants may alter brain function in schizophrenia
A collaborative study led by investigators from Massachusetts General Hospital (MGH) is giving what may be the first look at how interactions between genes underlie a key symptom of schizophrenia, impaired working memory.
Mental health linked to stillbirth and newborn deaths
Women with a history of serious mental illness are much more likely to have babies that are stillborn or die within the first month of life, new research reveals.
Pitt research identifies new target in brain for treating schizophrenia
Research from the University of Pittsburgh could expand the options for controlling schizophrenia by identifying a brain region that responds to more than one type of antipsychotic drug.
Research shows raised incidence of psychoses among migrant groups
Researchers examining the occurrence of psychoses among migrant groups have shown a raised incidence for all black and ethnic minority subgroups compared with white British counterparts, and reveal that the risk of psychoses for first and second generations varies by ethnicity.
First evidence that prenatal exposure to famine may lead to persistent epigenetic changes
A study initiated by researchers at Columbia University Mailman School of Public Health and the Leiden University Medical Center in the Netherlands suggests that prenatal exposure to famine can lead to epigenetic changes that may affect a person's health into midlife.
Membrane fusion at the synapse: Janus faced synaptotagmin-1 helps to keep the fast pace
Imagine a bathtub with two soap bubbles colliding but never fusing. Then you add detergent, and the surface of the water goes flat as the walls of the bubbles collapse and merge.
More Schizophrenia Current Events and Schizophrenia News Articles
 | Surviving Schizophrenia: A Manual for Families, Consumers, and Providers (4th Edition) by E. Fuller Torrey Since its first publication in 1983, Surviving Schizophrenia has become the standard reference book on the disease and has helped thousands of patients, their families and mental health professionals. In clear language, this much–praised and important book describes the nature, causes, symptoms, treatment and course of schizophrenia and also explores living with it from both the patient and the... |
 | The Complete Family Guide to Schizophrenia: Helping Your Loved One Get the Most Out of Life by Kim T. Mueser, Susan Gingerich Do people with schizophrenia ever get better? With the vast majority of those with the disorder dependent on their families for care, close relatives often grapple with that question. The Complete Family Guide to Schizophrenia inspires hope. Authors Kim T. Mueser, PhD, and Susan Gingerich, MSW, walk readers through a range of treatment and support options that can lead to a better life for the... |
 | Schizophrenia: Cognitive Theory, Research, and Therapy by Aaron T. Beck, Neil A. Rector, Neal Stolar, Paul Grant From Aaron T. Beck and colleagues, this is the definitive work on the cognitive model of schizophrenia and its treatment. The volume integrates cognitive-behavioral and biological knowledge into a state-of-the-science conceptual framework. It comprehensively examines the origins, development, and maintenance of key symptom areas: delusions, hallucinations, negative symptoms, and formal thought... |
 | Getting Your Life Back Together When You Have Schizophrenia by Roberta Temes |
 | Social Skills Training for Schizophrenia, Second Edition: A Step-by-Step Guide (TREATMENT MANUALS FOR PRACTITIONERS) by Alan S. Bellack, Kim T. Mueser, Susan Gingerich, Julie Agresta This popular manual presents an empirically tested format and ready-made curricula for skills training groups in a range of settings. Part I takes therapists and counselors step by step through assessing clients' existing skills, teaching new skills, and managing common treatment challenges. Part II comprises over 60 ready-to-photocopy skill sheets. Each sheet--essentially a complete lesson... |
 | Stalking Irish Madness: Searching for the Roots of My Family's Schizophrenia by Patrick Tracey In this powerful, sometimes harrowing, deeply felt story, Patrick Tracey journeys to Ireland to track the origin and solve the mystery of his Irish-American family's multigenerational struggle with schizophrenia.For most Irish Americans, a trip to Ireland is often an occasion to revisit their family's roots. But for Patrick Tracey, the lure of his ancestral home is a much more powerful need: part... |
 | Schizophrenia For Dummies (For Dummies (Health & Fitness)) by Jerome Levine, Irene S. Levine Practical tools for leading a happy, productive life Schizophrenia is a chronic, severe, and disabling mental disorder that afflicts one percent of the population, an estimated 2.5 million people in America alone. The firsthand advice in this reassuring guide will empower the families and caregivers of schizophrenia patients to take charge, offering expert advice on identifying the warning... |
 | Diagnosis: Schizophrenia by Rachel Miller, Susan Mason The disease is not fatal but few diagnoses have the capacity to instill as much fear in the hearts of patients and families. Here is a profoundly reassuring book that shows there can be life after a diagnosis of schizophrenia. The book includes thirty-five first-person accounts, along with chapters by professionals on a wide range of issues from hospitalization to rehabilitation. Jargon-free and... |
 | Anti-Oedipus: Capitalism and Schizophrenia by Gilles Deleuze, Felix Guattari |
 | Cognitive Therapy of Schizophrenia (Guides to Individualized Evidence-Based Treatment) by David G. Kingdon, Douglas Turkington Drawing on the authors' decades of influential work in the field, this highly practical volume presents an evidence-based cognitive therapy approach for clients with schizophrenia. Guidelines are provided for collaborative assessment and case formulation that enable the clinician to build a strong therapeutic relationship, establish reasonable goals, and tailor treatment to each client's needs.... |
| © 2008 BrightSurf.com |